Efficacy and Safety of Repeated Micropulse Trans-Scleral Dio
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to determine the efficacy and safety of repeated micropulse trans-scleral cyclophotocoagulation (MPTCP) for an Asian population with refractory glaucoma.

This is a retrospective case series of 43 eyes with severe glaucoma which underwent repeated MPTCP. Baseline parameters were taken from the visit just before the second MPTCP session. Success was defined as IOP of 6–21 mmHg or more than 20% reduction in intraocular pressure (IOP) without an increase in glaucoma medication from baseline, without further glaucoma re-operation, and less than 3 total MPTCP episodes.

The IOP, number of IOP-lowering medications and best-corrected visual acuity (BCVA) were documented pre and post-operatively. Post-operative complications were also analyzed.

Results:
--The mean age was 57.4±18.2 years with a mean follow-up duration of 28.9±27.5 months.

--Neovascular glaucoma was the most common type of glaucoma (18 eyes). The success rates at post-operative years 1, 2 and 3, and latest follow-up was 36.4%, 42.9%, 32.0% and 39.5%, respectively.

--The median survival time of repeat MPTCP was 4.6 months. Compared to the pre-operative mean IOP (35.2±11.0 mmHg), the mean IOP at post-operative years 1, 2 and 3, and latest follow-up, was 27.8±13.7 mmHg, 27.4±12.4, 31.8±13.2 and 27.1±13.8 mmHg respectively.

--The mean number of IOP-lowering medications was reduced from 3.3±0.9 pre-operatively to 2.8±1.3 at the final follow-up.

--Post-operative complications included prolonged hypotony (3 eyes [7.0%]) and phthisis bulbi (2 eyes [4.7%]).

Conclusively, Repeated MPTCP is at best moderately effective in lowering IOP for eyes with advanced glaucoma.

Source: https://journals.lww.com/glaucomajournal/Abstract/9000/Efficacy_and_Safety_of_Repeated_Micropulse.97584.aspx
Like
Comment
Share